SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
SOPHiA GENETICS (Nasdaq: SOPH) announced an expanded relationship with OncoHelix, a Canada-based research and diagnostics laboratory. OncoHelix will implement MSK-ACCESS® powered with SOPHiA DDM™, becoming the first laboratory in Canada to adopt this liquid biopsy solution. This expansion builds on OncoHelix's existing use of the SOPHiA DDM™ Platform for myeloid testing.
The new liquid biopsy solution will advance OncoHelix's oncology testing capabilities, offering an alternative to traditional solid tumor biopsy. It extracts cell-free DNA from blood plasma, revealing circulating tumor DNA, which can expedite clinical decisions and streamline monitoring. The implementation is expected to go live later this summer, supporting OncoHelix's mission to offer exceptional clinical-grade molecular and immune profile testing.
SOPHiA GENETICS (Nasdaq: SOPH) ha annunciato un rapporto ampliato con OncoHelix, un laboratorio di ricerca e diagnostica con sede in Canada. OncoHelix implementerà MSK-ACCESS® alimentato da SOPHiA DDM™, diventando il primo laboratorio in Canada ad adottare questa soluzione per biopsia liquida. Questa espansione si basa sull'uso esistente della piattaforma SOPHiA DDM™ per i test mieloidi.
La nuova soluzione per biopsia liquida migliorerà le capacità di test oncologici di OncoHelix, offrendo un'alternativa alla biopsia tradizionale dei tumori solidi. Estrae il DNA libero da cellule dal plasma sanguigno, rivelando il DNA tumorale circolante, il che può accelerare le decisioni cliniche e semplificare il monitoraggio. Si prevede che l'implementazione avrà luogo entro la fine dell'estate, supportando la missione di OncoHelix di offrire test di profilo molecolare e immunitario di qualità clinica eccezionale.
SOPHiA GENETICS (Nasdaq: SOPH) anunció una relación ampliada con OncoHelix, un laboratorio de investigación y diagnóstico con sede en Canadá. OncoHelix implementará MSK-ACCESS® impulsado por SOPHiA DDM™, convirtiéndose en el primer laboratorio en Canadá en adoptar esta solución de biopsia líquida. Esta expansión se basa en el uso existente de la Plataforma SOPHiA DDM™ para pruebas mieloides.
La nueva solución de biopsia líquida mejorará las capacidades de pruebas oncológicas de OncoHelix, ofreciendo una alternativa a la biopsia tradicional de tumores sólidos. Extrae ADN libre de células del plasma sanguíneo, revelando ADN tumoral circulante, lo que puede acelerar las decisiones clínicas y optimizar el monitoreo. Se espera que la implementación esté activa a finales de verano, apoyando la misión de OncoHelix de ofrecer pruebas de perfil molecular e inmunológico de calidad clínica excepcional.
SOPHiA GENETICS (Nasdaq: SOPH)는 캐나다에 본사를 둔 연구 및 진단 실험실인 OncoHelix와의 협력을 확대한다고 발표했습니다. OncoHelix는 SOPHiA DDM™로 구동되는 MSK-ACCESS®를 구현하여 캐나다에서 이 액체 생검 솔루션을 처음으로 채택한 실험실이 됩니다. 이 확장은 OncoHelix가 이미 사용하고 있는 SOPHiA DDM™ 플랫폼을 기반으로 한 것입니다.
새로운 액체 생검 솔루션은 OncoHelix의 종양학 테스트 능력을 향상시켜 전통적인 고형 종양 생검에 대한 대안을 제공합니다. 혈장으로부터 자유롭게 DNA를 추출하여 순환하는 종양 DNA를 밝혀내며, 이는 임상 결정을 신속하게 하고 모니터링을 간소화할 수 있습니다. 이 구현은 여름 말쯤 시작될 예정으로, OncoHelix가 뛰어난 임상 등급의 분자 및 면역 프로파일 테스트를 제공할 수 있도록 지원합니다.
SOPHiA GENETICS (Nasdaq: SOPH) a annoncé une relation élargie avec OncoHelix, un laboratoire de recherche et de diagnostic basé au Canada. OncoHelix mettra en œuvre MSK-ACCESS® alimenté par SOPHiA DDM™, devenant ainsi le premier laboratoire au Canada à adopter cette solution de biopsie liquide. Cette expansion s'appuie sur l'utilisation existante de la plateforme SOPHiA DDM™ pour les tests myéloïdes.
La nouvelle solution de biopsie liquide améliorera les capacités de test oncologique d'OncoHelix, offrant une alternative à la biopsie traditionnelle des tumeurs solides. Elle extrait l'ADN libre circulant du plasma sanguin, révélant l'ADN tumoral circulant, ce qui peut accélérer les décisions cliniques et faciliter le suivi. La mise en œuvre devrait être opérationnelle d'ici la fin de l'été, soutenant la mission d'OncoHelix d'offrir des tests de profils moléculaires et immunologiques de qualité clinique exceptionnels.
SOPHiA GENETICS (Nasdaq: SOPH) kündigte eine erweiterte Zusammenarbeit mit OncoHelix an, einem in Kanada ansässigen Forschungs- und Diagnoselabor. OncoHelix wird MSK-ACCESS® betrieben von SOPHiA DDM™ implementieren und wird das erste Labor in Kanada, das diese Flüssigbiopsie-Lösung übernimmt. Diese Erweiterung basiert auf der bestehenden Nutzung der SOPHiA DDM™ Plattform für myeloide Tests.
Die neue Flüssigbiopsie-Lösung wird die Onkologie-Testfähigkeiten von OncoHelix voranbringen und eine Alternative zur traditionellen Biopsie solider Tumoren bieten. Sie extrahiert zellfreies DNA aus Blutplasma und enthüllt zirkulierende Tumor-DNA, was klinische Entscheidungen beschleunigen und das Monitoring erleichtern kann. Die Implementierung wird voraussichtlich später in diesem Sommer in Betrieb genommen, um die Mission von OncoHelix zu unterstützen, außergewöhnliche klinische molekulare und immunologische Profiling-Tests anzubieten.
- Expansion of relationship with OncoHelix, potentially increasing SOPHiA GENETICS' market presence in Canada
- OncoHelix adopting MSK-ACCESS® powered with SOPHiA DDM™, showcasing product demand
- Diversification of SOPHiA GENETICS' product offerings in liquid biopsy solutions
- None.
The expanded partnership between SOPHiA GENETICS and OncoHelix marks a significant advancement in liquid biopsy technology for cancer diagnostics in Canada. This collaboration brings the sophisticated MSK-ACCESS® powered with SOPHiA DDM™ platform to OncoHelix, enhancing their capabilities in oncology testing.
Key points to consider:
- Liquid biopsy offers a less invasive alternative to traditional solid tumor biopsies, which is particularly beneficial for patients with limitations such as insufficient tissue material or poor tissue quality.
- The technology analyzes cell-free DNA (cfDNA) from blood plasma to detect circulating tumor DNA (ctDNA), potentially expediting clinical decisions and improving patient monitoring.
- MSK-ACCESS® powered with SOPHiA DDM™ involves deep sequencing of 146 key cancer-associated genes, combining SOPHiA GENETICS' analytics with Memorial Sloan Kettering Cancer Center's expertise in cancer genomics.
From a research perspective, this partnership could accelerate cancer research by providing more accessible and comprehensive genetic profiling. The ability to track treatment response and measure residual disease through liquid biopsy could lead to more personalized and effective cancer treatments.
However, it's important to note that while liquid biopsy technology is promising, it's still an evolving field. The sensitivity and specificity of these tests can vary depending on cancer type and stage. Investors should monitor clinical validation studies and real-world performance data as they become available.
This partnership expansion represents a strategic move for SOPHiA GENETICS in the competitive landscape of precision oncology. Here's why this development is noteworthy:
- Market Penetration: OncoHelix becoming the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ gives SOPHiA GENETICS a foothold in the Canadian market, potentially paving the way for further expansion.
- Product Adoption: The fact that OncoHelix is expanding its use of SOPHiA GENETICS' technology from myeloid testing to liquid biopsy suggests strong customer satisfaction and product efficacy.
- Market Positioning: By partnering with a recognized leader like OncoHelix, SOPHiA GENETICS strengthens its credibility in the precision oncology space.
The global liquid biopsy market is projected to grow significantly, with some estimates suggesting a CAGR of over
However, investors should be aware of the competitive landscape. Several other companies are also developing liquid biopsy technologies and the success of SOPHiA GENETICS will depend on the continued performance and differentiation of their platform.
While this partnership is a positive development, its financial impact may take time to materialize. Investors should look for future announcements regarding additional partnerships or increases in test volumes as indicators of market traction.
OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™
BOSTON and ROLLE, Switzerland, July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities. OncoHelix will be live on MSK-ACCESS® powered with SOPHiA DDM™ later this summer.
OncoHelix is based in Calgary, Canada, and offers specialized genomic and molecular testing services globally. OncoHelix works in partnership with the Hematology Translational Lab (HTL) at the University of Calgary and has helped significantly advance the University's precision oncology and immunology research pipelines.
"Our mission at OncoHelix is to offer exceptional clinical-grade molecular and immune profile testing. That mission is predicated on using the most cutting-edge technology to allow for the rapid validation of genomic panels, sequencing, and analysis," said Dr. Pinaki Bose, co-founder and Executive Vice President, OncoHelix. "The SOPHiA DDM™ Platform has supported our mission over the last year, and we look forward to implementing MSK-ACCESS® powered with SOPHiA DDM™ to advance our liquid biopsy offering."
Liquid biopsy testing provides an alternative testing method to traditional solid tumor biopsy, which can be especially helpful when patients are facing limitations such as insufficient material or poor tissue quality, or simply need a less invasive method of biopsy. Liquid biopsy testing extracts cell-free DNA (cfDNA) from blood plasma, revealing circulating tumor DNA (ctDNA). This approach, obtained through a simple blood draw, expedites clinical decisions, accelerates results for researchers and clinicians, and streamlines monitoring.
"OncoHelix has quickly become a trusted leader in precision oncology testing and that is due, in part, to its unrelenting focus on offering the most advanced technology solutions on the market," said John Carey, Managing Director, NORAM, SOPHiA GENETICS. "We are excited to expand our relationship with OncoHelix by offering this new liquid biopsy solution, and continue supporting the company's commitment to tackling cancer research head-on via targeted testing."
MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version of a highly validated ctDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK) that involves the deep sequencing of 146 key cancer-associated genes. The offering combines the sophisticated analytics, state-of-the-art algorithms, and global network of the SOPHiA DDM™ Platform, with the scientific and clinical expertise of MSK in cancer genomics to provide a best-in-class liquid biopsy solution.
For more information, visit SOPHiAGENETICS.com, or connect on LinkedIn. For more information on OncoHelix, visit oncohelix.org, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
SOURCE SOPHiA GENETICS
FAQ
What is the new product OncoHelix is implementing from SOPHiA GENETICS (SOPH)?
When will OncoHelix go live with MSK-ACCESS® powered with SOPHiA DDM™?
What are the benefits of the liquid biopsy solution offered by SOPHiA GENETICS (SOPH)?
How many genes does MSK-ACCESS® powered with SOPHiA DDM™ sequence?
